Developing receptor-targeted oncolytic RNA immunotherapies
ImmVirX is a clinical-stage oncology company developing receptor-targeted oncolytic RNA immunotherapies for cancers with high unmet need, with a particular focus on tumours with mutations in the MAP kinase (MAPK) pathway.
Advancing our pipeline
We are advancing IVX037 in clinical trials and preparing IVX055 for clinical development in cancers where patients have limited treatment options.
Our novel oncolytic RNA immunotherapies are designed to preferentially enter, replicate in and destroy cancer cells, while stimulating anti-tumour immune responses. Our bioselection platform selects viruses that use receptors expressed on tumour cells. This approach combines direct tumour cell destruction with changes in the tumour microenvironment that may support immune activity in both injected and non-injected tumours.
Our lead programme evaluates IVX037 in combination with a PD-1 inhibitor in microsatellite-stable colorectal cancer, with an increasing focus on KRAS/BRAF-mutant disease. IVX037 is also being evaluated in ovarian cancer. Our second candidate, IVX055, is being prepared for clinical development, while combinations with other agents, including RAS and RAF inhibitors, remain exploratory.
View our Corporate Investor Deck
In the News
Discover the latest news articles featuring ImmVirX, including research innovations, stories about our people and reports from the latest events.
